Association between perioperative blood transfusion and oncologic outcomes after curative surgery for renal cell carcinoma

Journal of Cancer

Volumn 7, Issue 8, 2016, Pages 965-972

  Park, Yong Hyun ^a   Kim, Yong June ^b   Kang, Seok Ho ^c   Kim, Hyeon Hoe ^d   Byun, Seok Soo ^e   Lee, Ji Youl ^a   Hong, Sung Hoo ^a  

^a The Catholic University of Korea   (South Korea)

^b Chungbuk National University College of Medicine   (South Korea)

^c Korea University College of Medicine   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

^e Seoul National University Bundang Hospital   (South Korea)

Author keywords

Perioperative blood transfusion; Prognosis; Renal cell carcinoma

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; BODY MASS; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER SURGERY; COMORBIDITY; ERYTHROCYTE CONCENTRATE; FEMALE; HOSPITALIZATION; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERIOPERATIVE BLOOD TRANSFUSION; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; RECURRENCE FREE SURVIVAL; TREATMENT OUTCOME; TUMOR NECROSIS; TUMOR VOLUME; UNIVARIATE ANALYSIS;

EID: 84980010262     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.15073     Document Type: Article

References (22)

1. Yang JC, Childs R. Immunotherapy for renal cell cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006; 24: 5576-83.
2. Santoni M, Berardi R, Amantini C, Burattini L, Santini D, Santoni G, et al. Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor. International journal of cancer Journal international du cancer. 2014; 134: 2772-7.
3. Ng CS, Novick AC, Tannenbaum CS, Bukowski RM, Finke JH. Mechanisms of immune evasion by renal cell carcinoma: tumor-induced T-lymphocyte apoptosis and NFkappaB suppression. Urology. 2002; 59: 9-14.
4. Opelz G, Terasaki PI. Poor kidney-transplant survival in recipients with frozen-blood transfusions or no transfusions. Lancet. 1974; 2: 696-8.
5. Gascon P, Zoumbos NC, Young NS. Immunologic abnormalities in patients receiving multiple blood transfusions. Annals of internal medicine. 1984; 100: 173-7.
6. Burrows L, Tartter P. Effect of blood transfusions on colonic malignancy recurrent rate. Lancet. 1982; 2: 662.
7. Choi JH, Chung HC, Yoo NC, Lee HR, Lee KH, Kim JH, et al. Perioperative blood transfusions and prognosis in patients with curatively resected locally advanced gastric cancer. Oncology. 1995; 52: 170-5.
8. Donohue JH, Williams S, Cha S, Windschitl HE, Witzig TE, Nelson H, et al. Perioperative blood transfusions do not affect disease recurrence of patients undergoing curative resection of colorectal carcinoma: a Mayo/North Central Cancer Treatment Group study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1995; 13: 1671-8.
9. Little AG, Wu HS, Ferguson MK, Ho CH, Bowers VD, Segalin A, et al. Perioperative blood transfusion adversely affects prognosis of patients with stage I non-small-cell lung cancer. American journal of surgery. 1990; 160: 630-2; discussion 3.
10. Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. The Cochrane database of systematic reviews. 2006: CD005033.
11. Wang CC, Iyer SG, Low JK, Lin CY, Wang SH, Lu SN, et al. Perioperative factors affecting long-term outcomes of 473 consecutive patients undergoing hepatectomy for hepatocellular carcinoma. Annals of surgical oncology. 2009; 16: 1832-42.
12. Linder BJ, Thompson RH, Leibovich BC, Cheville JC, Lohse CM, Gastineau DA, et al. The impact of perioperative blood transfusion on survival after nephrectomy for non-metastatic renal cell carcinoma (RCC). BJU international. 2014; 114: 368-74.
13. Soubra A, Zabell JR, Adejoro O, Konety BR. Effect of Perioperative Blood Transfusion on Mortality for Major Urologic Malignancies. Clinical genitourinary cancer. 2014.
14. Moffat LE, Sunderland GT, Lamont D. Blood transfusion and survival following nephrectomy for carcinoma of kidney. British journal of urology. 1987; 60: 316-9.
15. Jakobsen EB, Eickhoff JH, Andersen JP, Ottesen M. Perioperative blood transfusion does not affect survival after operation for renal cell cancer. European urology. 1994; 26: 145-8.
16. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Annals of surgical oncology. 2010; 17: 1471-4.
17. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, et al. The Heidelberg classification of renal cell tumours. The Journal of pathology. 1997; 183: 131-3.
18. Patel HB, Nasir FA, Nash GF, Scully MF, Kakkar AK. Enhanced angiogenesis following allogeneic blood transfusion. Clinical and laboratory haematology. 2004; 26: 129-35.
19. Nielsen HJ, Werther K, Mynster T, Brunner N. Soluble vascular endothelial growth factor in various blood transfusion components. Transfusion. 1999; 39: 1078-83.
20. Refaai MA, Blumberg N. Transfusion immunomodulation from a clinical perspective: an update. Expert review of hematology. 2013; 6: 653-63.
21. Rodey GE. Blood transfusions and their influence on renal allograft survival. Progress in hematology. 1986; 14: 99-122.
22. Blumberg N, Heal JM. Transfusion and host defenses against cancer recurrence and infection. Transfusion. 1989; 29: 236-45.